Announcements Trials

Browse Landscape

Phase

Status

Recruiting 2 Not yet recruiting 2 Unknown 1 Terminated 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 594 Carcinoma, Renal Cell 276 Urinary Bladder Neoplasms 175 Kidney Neoplasms 112 Neoplasms 101 Neoplasm Metastasis 94 Carcinoma, Non-Small-Cell Lung 94 Carcinoma, Transitional Cell 86 Melanoma 85 Breast Neoplasms 83 Ovarian Neoplasms 64 Lung Neoplasms 50 Colorectal Neoplasms 50 Pancreatic Neoplasms 43 Stomach Neoplasms 40 Sarcoma 37 Squamous Cell Carcinoma of Head and Neck 35 Triple Negative Breast Neoplasms 31 Testicular Neoplasms 29 Uterine Cervical Neoplasms 27 Esophageal Neoplasms 26 Carcinoma, Hepatocellular 26 Head and Neck Neoplasms 24 Non-Muscle Invasive Bladder Neoplasms 23 Small Cell Lung Carcinoma 22 Colonic Neoplasms 20 Urologic Neoplasms 17 Neuroblastoma 17 Multiple Myeloma 17 Endometrial Neoplasms 17

Interventions

tremelimumab 1 durvalumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Muscle-invasive Bladder Cancer × Genitourinary × Clear all

NCT03234153 2020-06-17

NITIMIB

Insel Gruppe AG, University Hospital Bern

Phase 2 Terminated

Muscle-invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡